Hutchison China Meditech Ltd (HCM)

13.18
NASDAQ : Health Care
Prev Close 13.18
Day Low/High 0.00 / 0.00
52 Wk Low/High 9.80 / 14.70
Avg Volume 22.60K
Exchange NASDAQ
Shares Outstanding 120.57M
Market Cap 1.58B
EPS -0.30
Div & Yield N.A. (N.A)

Chi-Med Completes Enrollment Of 416 Patients In Pivotal Phase III FRESCO Trial With Fruquintinib In Colorectal Cancer

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq:HCM) today announces that it has completed patient enrollment of FRESCO, its Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced or...

Chi-Med To Participate In Two Healthcare Investor Conferences In May

Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announced that Chief Executive Officer Christian Hogg will present a corporate overview at two healthcare investor conferences in May.

Hutchison China MediTech Limited Announces Exercise Of Overallotment Option

Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares ("ADSs") on the Nasdaq Global Select Market (the "Offering") have exercised their...

Chi-Med Initiates First-in-Human Clinical Trial Of Novel PI3K Inhibitor HMPL-689

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the first-in-human ("FIH") Phase I clinical trial of...

Chi-Med Initiates Sulfatinib Phase III Registration Study In Pancreatic Neuroendocrine Tumor Patients

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of sulfatinib...

Hutchison China MediTech Limited Announces Pricing Of U.S. Public Offering Of ADSs

Hutchison China MediTech Limited ("Chi-Med") (AIM:HCM) announces the pricing of its U.

Hanover Capital Delays Filing

The company cites conditions in the mortgage market.